Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiation for Locally Advanced HNSCC
NCT00702481Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Apr 2008
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Centre Singapore. Primary endpoint: Response Rate at 16 weeks. Started Apr 2008; status: completed.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00702481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702481.